Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Direct Meds vs Hims & Hers

Direct Meds
Graded #27

Higher grade

vs+2
Hims & Hers
Graded #28

Lower grade

The verdict

Direct Meds takes it — 82/100 to 80/100, but only just.

Direct Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. One of the few programs offering an oral/sublingual route alongside injectable — semaglutide from ~$179 sublingual (~$297 injectable), tirzepatide ~$224/$399, with an intro promo near $147, all-inclusive and no membership. Hims & Hers is close behind and may still be the better fit — see the factor split below.

Assume any provider we list may compensate us — we may earn a commission at no cost to you. It never changes the WeighScore.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueDirect Meds +3
85
82
Dose & formulationDirect Meds +10
88
78
Clinical oversightHims & Hers +2
80
82
Labs & monitoringHims & Hers +2
78
80
FulfillmentHims & Hers +4
80
84
Contract termsEven
80
80
Direct Meds · left barHims & Hers · right bar

The numbers

MetricDirect MedsHims & Hers
WeighScore82/10080/100
GradeB−B−
Scorecard rank#27#28
Semaglutide$179/mo$199/mo
Tirzepatide$224/moNot disclosed
CoverageNot publicly listedAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
Direct Meds

Graded #27 · B−

Strengths

  • Rare oral/sublingual option in addition to injectable
  • All-inclusive pricing with no separate membership fee
  • Both molecules — semaglutide and tirzepatide
  • Intro promotional pricing near $147

Where it loses points

  • Compounded only — not FDA-approved
  • Pricing is company-stated, not independently live-verified
  • Newer and somewhat ambiguous (operates across multiple domains)
  • States served are not disclosed
Hims & Hers

Graded #28 · B−

Strengths

  • Nationwide
  • Polished app
  • Strong brand trust

Where it loses points

  • Tirzepatide pricing inconsistently disclosed
  • Industry-wide compounding scrutiny

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 31 providers, CoreAge Rx grades highest at 94/100 (A). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard